Ubaldo Bonuccelli

Ubaldo Bonuccelli's AcademicInfluence.com Rankings

Ubaldo Bonuccelli

Medical

#3274

World Rank

#3736

Historical Rank

Neurology

#301

World Rank

#383

Historical Rank

medical Degrees

Download Badge

Medical

Ubaldo Bonuccelli's Degrees

Doctorate Neurology University of Florence

Why Is Ubaldo Bonuccelli Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ubaldo Bonuccelli's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease (2014) (1230)
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (1073)
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) (693)
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study (2007) (543)
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients (2007) (511)
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial (2010) (372)
Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease (2013) (305)
Perioperative atrial fibrillation and the long-term risk of ischemic stroke. (2014) (267)
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease (2006) (256)
Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. (2008) (235)
A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA (2004) (195)
Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians (2005) (190)
REM sleep behaviour disorder in Parkinson’s disease: a questionnaire-based study (2005) (166)
Psychiatric comorbidity in a population of Parkinson's disease patients (2004) (160)
Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study (2001) (156)
Oxidative damage and cytogenetic analysis in leukocytes of Parkinson’s disease patients (2002) (149)
Impulsivity and compulsivity in drug‐naïve patients with Parkinson's disease (2011) (140)
Psychiatric Comorbidity and Psychosocial Stress in Patients with Tension-Type Headache From Headache Centers in Italy (1999) (128)
Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease (2012) (128)
The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration (2005) (127)
Dopaminergic Modulation of Visual-Spatial Working Memory in Parkinson’s Disease (2003) (124)
Alzheimer and his disease: a brief history (2011) (123)
Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. (2009) (121)
Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter study (2013) (121)
Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study (2017) (120)
Preferential occurrence of chromosome 21 malsegregation in peripheral blood lymphocytes of Alzheimer disease patients (1999) (119)
Paroxetine in Parkinson’s disease: Effects on motor and depressive symptoms (2000) (118)
Depressive symptoms in Parkinson's disease. (2012) (116)
MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. (2014) (115)
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation (2011) (111)
A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. (1999) (109)
SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study (2001) (109)
Early DEtection of wEaring off in Parkinson disease: the DEEP study. (2014) (108)
A molecular signature in blood identifies early Parkinson’s disease (2012) (107)
White matter hyperintensities in Parkinson's disease. Clinical correlations. (1995) (106)
Orthostatic hypotension in de novo Parkinson disease. (2003) (105)
New pharmacologic horizons in the treatment of Parkinson disease (2006) (103)
Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease (2001) (102)
Theory of Mind in Parkinson's disease (2011) (100)
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease (2019) (98)
Improvement of motor function in early Parkinson disease by safinamide (2004) (98)
Mild cognitive impairment and cognitive reserve in Parkinson's disease. (2011) (97)
ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease (2017) (97)
Spontaneous and induced aneuploidy in peripheral blood lymphocytes of patients with Alzheimer’s disease (1997) (91)
Direct genetic evidence for involvement of tau in progressive supranuclear palsy (1998) (87)
Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson’s disease: a review (2013) (87)
Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. (1997) (83)
Differences in nigro‐striatal impairment in clinical variants of early Parkinson’s disease: evidence from a FP‐CIT SPECT study (2010) (82)
Cytogenetic alterations in lymphocytes of Alzheimer's disease and Parkinson's disease patients (2002) (82)
Smoking habits in multiple system atrophy and progressive supranuclear palsy (2000) (81)
How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. (2007) (81)
A Single-Center, Cross-Sectional Prevalence Study of Impulse Control Disorders in Parkinson Disease: Association With Dopaminergic Drugs (2013) (78)
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. (2006) (78)
Dopamine Transporter SPECT Imaging in Corticobasal Syndrome (2011) (78)
Personality traits in patients with Parkinson’s disease: assessment and clinical implications (2012) (77)
Comparison of 3T and 7T Susceptibility-Weighted Angiography of the Substantia Nigra in Diagnosing Parkinson Disease (2015) (77)
Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging (2007) (77)
A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients (2015) (74)
Role of dopamine receptor agonists in the treatment of early Parkinson's disease. (2009) (74)
Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study (1994) (74)
A Whole-Brain Analysis in De Novo Parkinson Disease (2008) (73)
Progression of tremor in early stages of Parkinson’s disease: a clinical and neuroimaging study (2018) (73)
Headache, panic disorder and depression: comorbidity or a spectrum? (1995) (71)
Association between amantadine and the onset of dementia in Parkinson's disease (2006) (71)
Progression of brain atrophy in the early stages of Parkinson's disease: A longitudinal tensor‐based morphometry study in de novo patients without cognitive impairment (2014) (71)
Changes in Pattern Electroretinograms to Equiluminant Red-Green and Blue-Yellow Gratings in Patients with Early Parkinson’s Disease (2003) (69)
Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints (2018) (69)
Clozapine in Parkinson's disease tremor (1997) (69)
IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients (2012) (68)
Clozapine in Huntington's chorea (1994) (66)
Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases (2017) (66)
Prevalence and impact of COVID-19 in Parkinson’s disease: evidence from a multi-center survey in Tuscany region (2020) (64)
Chromosome and oxidative damage biomarkers in lymphocytes of Parkinson's disease patients. (2001) (63)
Case–control study of multiple system atrophy (2005) (62)
Decision making in de novo Parkinson's disease (2010) (62)
Essential tremor is a neurodegenerative disease (2012) (62)
Cognitive impairment and cardiovascular disease: so near, so far. (2014) (62)
Acute and chronic effects of clozapine in essential tremor (1999) (61)
Parkinson's Disease and pathological gambling: Results from a functional MRI study (2010) (61)
Affective symptoms and cognitive functions in Parkinson's disease (2012) (60)
Spontaneous and induced chromosome damage in somatic cells of sporadic and familial Alzheimer's disease patients. (2001) (59)
Spinocerebellar ataxia type 2 in southern Italy: a clinical and molecular study of 30 families (1999) (59)
Methylation analysis of multiple genes in blood DNA of Alzheimer’s disease and healthy individuals (2015) (58)
Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. (2002) (57)
The relationship between cerebral vascular disease and parkinsonism: The VADO study. (2012) (56)
Non-rapid eye movement sleep instability in mild cognitive impairment: a pilot study. (2015) (55)
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features (2008) (53)
Clinical Pharmacokinetics of Cabergoline (2003) (53)
Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients (2001) (53)
Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia (2009) (53)
Presynaptic nigro-striatal function in a group of Alzheimer’s disease patients with parkinsonism: evidence from a dopamine transporter imaging study (2004) (53)
Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction (2012) (51)
Iowa Gambling Task in Parkinson's Disease (2011) (51)
Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy (2008) (50)
Hearing loss and cognitive decline in older adults: questions and answers (2014) (49)
Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1 (2016) (47)
Comparing dopamine agonists in Parkinson's disease (2003) (47)
Epidemiology of multiple system atrophy (2001) (47)
White Matter MRI Hyperintensities in a Hundred and Twenty-Nine Consecutive Migraine Patients (1994) (46)
Impulse control disorders in Parkinson’ disease: the role of personality and cognitive status (2012) (45)
Cytogenetic analysis oxidative damage in lymphocytes of Parkinson's disease patients (2001) (45)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by ethanol or acetaldehyde. (1987) (44)
Levodopa response in dementia with lewy bodies: a 1-year follow-up study. (2010) (44)
Descriptive Epidemiologic Study of Epilepsy Syndromes in a District of Northwest Tuscany, Italy (1991) (44)
IV amantadine improves chorea in Huntington’s disease An acute randomized, controlled study (2003) (44)
Spectrum of addictions in Parkinson’s disease: from dopamine dysregulation syndrome to impulse control disorders (2010) (44)
Species differences in the role of excitatory amino acids in experimental parkinsonism (1997) (43)
Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers (2018) (43)
Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease (2017) (42)
Abnormal response to photic stimulation in Juvenile Myoclonic Epilepsy: An EEG‐fMRI study (2014) (41)
Late (Complicated) Parkinson's Disease (2010) (40)
The Neuroanatomy of the Reticular Nucleus Locus Coeruleus in Alzheimer’s Disease (2017) (40)
Epidemiology of progressive supranuclear palsy (2001) (40)
Oxidative stress and APO E polymorphisms in Alzheimer's disease and in mild cognitive impairment (2013) (40)
Chromatic pattern-reversal electroretinograms (ChPERGs) are spared in multiple system atrophy compared with Parkinson’s disease (2006) (40)
The Epidemiology and Clinical Manifestations of Dysexecutive Syndrome in Parkinson’s Disease (2012) (40)
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease (2006) (40)
α-Synuclein Heterocomplexes with β-Amyloid Are Increased in Red Blood Cells of Parkinson’s Disease Patients and Correlate with Disease Severity (2018) (40)
Dextromethorphan and parkinsonism (1992) (39)
Influences of dopaminergic treatment on motor cortex in Parkinson disease: A MRI/MRS study (2007) (39)
Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study (2008) (39)
Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease (2019) (38)
Amitriptyline and Dexamethasone Combined Treatment in Drug-Induced Headache (1996) (38)
Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efﬁcacy, safety and patient selection. (2012) (38)
Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports (2001) (38)
A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease (1995) (38)
Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in Parkinsonian patients (2011) (38)
Quantitative susceptibility mapping in atypical Parkinsonisms (2019) (37)
Environmental factors and Parkinson's disease: a case-control study in the Tuscany region of Italy. (2004) (37)
Dopamine agonists in the treatment of Parkinson’s disease (2006) (36)
Orbital and ventromedial prefrontal cortex functioning in Parkinson’s disease: Neuropsychological evidence (2012) (36)
Meta-analysis of genetic association with diagnosed Alzheimer’s disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing (2018) (36)
Alzheimer's Pathogenesis and Its Link to the Mitochondrion (2015) (36)
Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer’s disease (2003) (36)
The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases (1999) (35)
Plasmatic oxidative stress biomarkers in multiple sclerosis: relation with clinical and demographic characteristics. (2015) (35)
Clinical outcome and magnetic resonance imaging of carbon monoxide intoxication. A long-term follow-up study (1999) (35)
Genetics of ischaemic stroke in young adults (2014) (35)
Prevalence of headache syndromes in panic disorder. (1999) (34)
The genetics of ataxia: through the labyrinth of the Minotaur, looking for Ariadne’s thread (2014) (34)
Twinkle mutation in an Italian family with external progressive ophthalmoplegia and parkinsonism: A case report and an update on the state of art (2013) (34)
Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats. (2003) (34)
α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects (2018) (33)
The relation between EMG activity and kinematic parameters strongly supports a role of the action tremor in parkinsonian bradykinesia (2001) (33)
Operationalizing mild cognitive impairment criteria in small vessel disease: the VMCI-Tuscany Study (2016) (33)
Excessive daytime sleepiness and fatigue in neurological disorders (2019) (33)
Decreased and increased cortical activation coexist in de novo Parkinson's disease (2010) (33)
Variant of Rett Syndrome and CDKL5 Gene: Clinical and Autonomic Description of 10 Cases (2012) (32)
Morphometric and functional MRI changes in essential tremor with and without resting tremor (2015) (32)
Caudate dopaminergic denervation and visual hallucinations: evidence from a ¹²³I-FP-CIT SPECT study. (2014) (32)
Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. (2014) (32)
Amantadine in Huntington's disease: open-label video-blinded study (2002) (32)
The association between motor subtypes and alexithymia in de novo Parkinson’s disease (2011) (31)
Apomorphine test for dopaminergic responsiveness: A dose assessment study (1993) (31)
"Parkinson-dementia" diseases: a comparison by double tracer SPECT studies. (2009) (31)
Alexithymia Is Associated with Depression in de novo Parkinson’s Disease (2011) (31)
Early (Uncomplicated) Parkinson's Disease (2010) (31)
Pergolide in the treatment of patients with early and advanced Parkinson's disease. (2002) (31)
Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: a SPECT follow-up study. (2013) (30)
How Aware Are Migraineurs of Their Triggers? (2013) (30)
Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers (2005) (30)
Hypoactivation of the primary sensorimotor cortex in de novo Parkinson’s disease (2012) (30)
Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease. (1999) (30)
Activity-Based Diary for Parkinson's Disease (2002) (30)
The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases (2020) (30)
Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes (2007) (30)
Triggers in Allodynic and Non‐Allodynic Migraineurs. A Clinic Setting Study (2013) (29)
Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects. (1985) (29)
Vascular factors and mitochondrial dysfunction: a central role in the pathogenesis of Alzheimer's disease. (2012) (29)
Mexiletine in the Treatment of Torticollis and Generalized Dystonia (2000) (29)
Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test (2006) (29)
Affective theory of mind in patients with Parkinson's disease (2013) (29)
Serotonergic antidepressant drugs and L‐dopa‐induced dyskinesias in Parkinson's disease (2015) (28)
Alteration of affective Theory of Mind in amnestic mild cognitive impairment. (2013) (28)
A review of adverse events linked to dopamine agonists in the treatment of Parkinson’s disease (2016) (28)
The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease (2013) (27)
Paraneoplastic choreic syndrome during non‐Hodgkin's lymphoma (2000) (27)
Prefrontal cortex, dopamine, and jealousy endophenotype (2012) (27)
Recommendations of the Sleep Study Group of the Italian Dementia Research Association (SINDem) on clinical assessment and management of sleep disorders in individuals with mild cognitive impairment and dementia: a clinical review (2014) (27)
Platelet monoamine oxidase B activity in parkinsonian patients. (1990) (26)
Social cognition in Juvenile Myoclonic Epilepsy (2016) (26)
Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (26)
Mapping Cortical Degeneration in ALS with Magnetization Transfer Ratio and Voxel-Based Morphometry (2013) (26)
Diagnosis of possible mild cognitive impairment in Parkinson's disease: validity of the SCOPA-Cog. (2013) (25)
A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease (2012) (25)
Treatment of Patients With Tardive Dystonia With Olanzapine (2002) (25)
Behavioral and Psychological Symptoms of Dementia: Factor Analysis and Relationship with Cognitive Impairment (2012) (25)
Dopamine agonists and delusional jealousy in Parkinson's disease: A cross‐sectional prevalence study (2012) (25)
Brain perfusion effects of cholinesterase inhibitors in Parkinson’s disease with dementia (2006) (25)
Clinical features associated with ictal osmophobia in migraine (2014) (24)
Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. (2001) (24)
Mesolimbic dopaminergic dysfunction in Parkinson’s disease depression: evidence from a 123I-FP-CIT SPECT investigation (2015) (24)
Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition. (2016) (24)
Hereditary spastic paraparesis in adults. A clinical and genetic perspective from Tuscany (2014) (24)
[Diurnal worsening in Parkinson patients treated with levodopa]. (1991) (23)
Biomarker-guided classification scheme of neurodegenerative diseases (2016) (23)
Nummular headache dramatically responsive to indomethacin (2010) (23)
Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases (2020) (23)
Long-term Follow-up after Flunarizine or Nimodipine Discontinuation in Migraine Patients (1996) (23)
Cerebral microbleeds in patients with mild cognitive impairment and small vessel disease: The Vascular Mild Cognitive Impairment (VMCI)-Tuscany study (2016) (23)
Possible Involvement of Dopaminergic Mechanisms in the Antimigraine Action of Flunarizine (1990) (23)
Thyroid hormone levels in the cerebrospinal fluid correlate with disease severity in euthyroid patients with Alzheimer’s disease (2017) (22)
Gait dynamics in Pisa syndrome and Camptocormia: The role of stride length and hip kinematics. (2017) (22)
Reliability of administrative data for the identification of Parkinson’s disease cohorts (2015) (22)
Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal 123I-FP-CIT SPECT study. (2020) (22)
Apomorphine hydrochloride for the treatment of Parkinson’s disease (2015) (21)
Antipsychotic drugs in Huntington’s disease (2017) (21)
Potential Diagnostic Value of Red Blood Cells α-Synuclein Heteroaggregates in Alzheimer’s Disease (2019) (20)
A longitudinal study of polysomnographic variables in patients with mild cognitive impairment converting to Alzheimer's disease (2019) (20)
Flunarizine in Migraine Prophylaxis: Predictive Factors for A Positive Response (1998) (20)
A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis (2015) (20)
Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease (2020) (19)
Late whiplash syndrome: a clinical and magnetic resonance imaging study. (1999) (19)
Clinical diagnosis of multiple system atrophy: level of agreement between Quinn's criteria and the consensus conference guidelines (2001) (19)
The hOGG1 Ser326Cys polymorphism is not associated with sporadic Parkinson's disease (2010) (19)
Naloxone partly counteracts apomorphine side effects. (1991) (19)
Seven tesla MRI of the substantia nigra in patients with rapid eye movement sleep behavior disorder. (2017) (19)
Domperidone‐induced acute dystonia and polycystic ovary syndrome (1991) (18)
‘Indotest’ in Atypical Hemicrania Continua (2008) (18)
What is the role for EEG after sleep deprivation in the diagnosis of epilepsy? Issues, controversies, and future directions (2014) (18)
Different effects of levodopa and apomorphine on blink reflex recovery cycle in essential blepharospasm. (1997) (18)
Observational study of sleep-related disorders in Italian patients with Parkinson’s disease: usefulness of the Italian version of Parkinson’s disease sleep scale (2012) (18)
Cognitive correlates of negative symptoms in behavioral variant frontotemporal dementia: implications for the frontal lobe syndrome (2013) (18)
Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Single‐Photon Emission Computed Tomography Study (2020) (18)
Identification and Determination of 3,4‐Dihydroxyphenylacetaldehyde, the Dopamine Metabolite, in In Vivo Dialysate from Rat Striatum (1996) (18)
Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease. (1997) (18)
Subcutaneous apomorphine for neuroleptic malignant syndrome. (2006) (17)
Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report (2015) (17)
Disappearance of skin lipofuscin storage and marked clinical improvement in adult onset coeliac disease and severe vitamin E deficiency after chronic vitamin E megatherapy. (1996) (17)
Postpartum Headache Due to Spontaneous Cervical Artery Dissection (2011) (17)
Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between α-synucleinopathies (2020) (17)
α-Synuclein Aggregated with Tau and β-Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise (2018) (17)
Excitatory amino acids and MPTP toxicity. (1996) (17)
Nonmotor symptoms in Parkinson's disease: the dark side of the moon (2010) (17)
IV amantadine improves chorea in Huntington’s disease: An acute randomized, controlled study (2003) (17)
Epilepsy occurrence in patients with Alzheimer’s disease: clinical experience in a tertiary dementia center (2016) (17)
Transcranial Doppler Ultrasound in Migraine and Tension-Type Headache After Apomorphine Administration: Double-Blind Crossover Versus Placebo Study (1995) (17)
Platelet peripheral benzodiazepine receptors are decreased in Parkinson's disease. (1991) (17)
Neuroleptic malignant syndrome: further lessons from a case report. (2010) (17)
Vascular Function Is Improved After an Environmental Enrichment Program: The Train the Brain–Mind the Vessel Study (2018) (16)
Platelet 3H-Imipramine Binding and Sulphotransferase Activity in Primary Headache (1994) (16)
Nigral involvement in atypical parkinsonisms: evidence from a pilot study with ultra-high field MRI (2016) (16)
Role of dopamine agonists in Parkinson’s disease: an update (2007) (16)
Locus Coeruleus Magnetic Resonance Imaging in Neurological Diseases (2020) (16)
Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia. (2014) (16)
Brain Aβ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD (2019) (16)
Treatment of epilepsy in patients with Alzheimer’s disease (2017) (16)
Expanding the clinical phenotype of DYT5 mutations: Is multiple system atrophy a possible one? (2013) (16)
A single center study: Aβ42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting (2017) (16)
The neuropsychological correlates of pathological lying: evidence from behavioral variant frontotemporal dementia (2011) (16)
Evidences of Reduced Antioxidant Activity in Patients With Chronic Migraine and Medication‐Overuse Headache (2015) (15)
Prevalence of Parkinson's disease and other types of parkinsonism in the Aeolian Archipelago, Sicily. (2008) (15)
Methylation analysis of DNA repair genes in Alzheimer’s disease (2017) (15)
Neuroendocrine evaluation in catamenial epilepsy. (1986) (15)
Olfactory evaluation in Mild Cognitive Impairment: correlation with neurocognitive performance and endothelial function (2017) (15)
Nigral involvement and nigrostriatal dysfunction in Huntington's disease: evidences from an MRI and SPECT study. (2013) (15)
Oxidative Stress Assessment in Alzheimer’s Disease: A Clinic Setting Study (2018) (15)
Insomnia and hot flashes. (2019) (15)
Diagnosis, assessment and management of delusional jealousy in Parkinson’s disease with and without dementia (2013) (15)
Current treatment and future prospects of dopa-induced dyskinesias. (2015) (15)
A combination of CSF tau ratio and midsaggital midbrain-to-pons atrophy for the early diagnosis of progressive supranuclear palsy. (2010) (15)
Phenobarbital in the prophylaxis of late posttraumatic seizures (1992) (15)
Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease (1990) (15)
Molecular implications of the human glutathione transferase A-4 gene (hGSTA4) polymorphisms in neurodegenerative diseases. (2005) (14)
Preferential occurrence of attacks during night sleep and/or upon awakening negatively affects migraine clinical presentation. (2015) (14)
Cyclic alternating pattern and interictal epileptiform discharges during morning sleep after sleep deprivation in temporal lobe epilepsy (2017) (14)
Myopathic involvement and mitochondrial pathology in Kennedy disease and in other motor neuron diseases. (2014) (14)
fMRI changes in cortical activation during task performance with the unaffected hand partially reverse after ropinirole treatment in de novo Parkinson's disease. (2013) (13)
Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine (2019) (13)
Involvement of monoamine oxidase enzymes in the action of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, a selective neurotoxin, in the squirrel monkey: Binding and biochemical studies (1986) (13)
Comparison of the Unified Parkinson's Disease Rating Scale and the Short Parkinson's Evaluation Scale in Patients With Parkinson's Disease After Levodopa Loading (2002) (13)
Effect of naloxone on body temperature in postmenopausal women with Parkinson's disease. (1990) (13)
Dextromethorphan prevents the diethyldithiocarbamate enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice (2003) (13)
A neurotropic approach to the treatment of multi-infarct dementia using L-α-glycerylphosphorylcholine (1992) (13)
Event-Based Prospective Memory in Newly Diagnosed, Drug-Naive Parkinson's Disease Patients (2011) (13)
No evidence of association between CAG expansions and essential tremor in a large cohort of Italian patients (2001) (13)
The mtDNA A8344G "MERRF" mutation is not a common cause of sporadic Parkinson disease in Italian population. (2008) (13)
Bilateral thalamic infarct caused by spontaneous vertebral artery dissection in pre-eclampsia with HELLP syndrome: a previously unreported association. (2012) (13)
3-T Magnetic Resonance Angiography in Primary Angiitis of the Central Nervous System (2013) (13)
Thyroid function and autoimmunity in Parkinson's disease: a study of 101 patients. (1999) (12)
Alexithymia is associated with impulsivity in newly-diagnosed, drug-naïve patients with Parkinson's disease: an affective risk factor for the development of impulse-control disorders? (2012) (12)
Cerebral sinus venous thrombosis: clinical and pathogenetic perspectives from Tuscany (2015) (12)
Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: a case series. (2014) (12)
Reduced luteinizing hormone secretion in women with Parkinson's disease (1990) (12)
Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement. (2006) (12)
Phenobarbital prophylaxis of post traumatic epilepsy (1979) (12)
Bedtime cabergoline in Parkinson’s disease patients with excessive daytime sleepiness induced by dopamine agonists (2003) (12)
Alexithymia may modulate decision making in patients with de novo Parkinson's disease. (2011) (12)
Social cognition in idiopathic generalized epilepsies and potential neuroanatomical correlates (2019) (12)
Apomorphine in malignant syndrome due to levodopa withdrawal (1992) (12)
A case of sarcoidosis presenting as a non‐specific intramedullary lesion (2007) (12)
‘Airlplane headache’ with aura (2010) (11)
Multicenter Study on Sleep and Circadian Alterations as Objective Markers of Mild Cognitive Impairment and Alzheimer's Disease Reveals Sex Differences. (2020) (11)
Altered neuroendocrine regulation of luteinizing hormone secretion in postmenopausal women with Parkinson's disease. (1991) (11)
Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype (2008) (11)
Effect of metadoxine on striatal dopamine levels in C57 Black mice (1993) (11)
MiRNA-15b and miRNA-125b are associated with regional Aβ-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints (2021) (11)
Epidemiology and cerebrovascular events related to cervical and intracranial arteries dissection: the experience of the city of Pisa (2017) (11)
Application of the DSM-5 Criteria for Major Neurocognitive Disorder to Vascular MCI Patients (2018) (10)
Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines (2012) (10)
Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers (2020) (10)
Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson’s disease (2013) (10)
Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease? (2017) (10)
Oxidative Stress in Cerebral Small Vessel Disease Dizziness Patients, Basally and After Polyphenol Compound Supplementation (2018) (10)
Cerebellar Ataxia with Complete Clinical Recovery and Resolution of MRI Lesions Related to Central Pontine Myelinolysis: Case Report and Literature Review (2010) (10)
Impact of ApoE Polymorphism and Physical Activity on Plasma Antioxidant Capability and Erythrocyte Membranes (2019) (10)
Advances in the pharmacotherapeutic management of dementia with Lewy bodies (2018) (10)
Aerobic Exercise and Healthy Nutrition as Neuroprotective Agents for Brain Health in Patients with Parkinson’s Disease: A Critical Review of the Literature (2020) (10)
Influence of physical exercise on β-amyloid, α-synuclein and tau accumulation: an in vitro model of oxidative stress in human red blood cells. (2017) (10)
Effects of combined training on neuropsychiatric symptoms and quality of life in patients with cognitive decline (2019) (9)
Present and Future of Ultra-High Field MRI in Neurodegenerative Disorders (2018) (9)
[Sleep in progressive supranuclear palsy]. (1982) (9)
Clinical Correlates of Cerebral Amyloid Deposition in Parkinson's Disease Dementia: Evidence from a PET Study. (2019) (9)
Brain-Derived Neurotrophic Factor (BDNF) and Serotonin Transporter (SERT) in Platelets of Patients with Mild Huntington's Disease: Relationships with Social Cognition Symptoms. (2018) (9)
ELECTROPHYSIOLOGICAL EVALUATION OF GENITO-SPHINCTERIC DYSFUNCTION IN MULTIPLE SYSTEM ATROPHY (2003) (9)
Disruption of sleep-wake continuum in myotonic dystrophy type 1: Beyond conventional sleep staging (2018) (9)
The arginine growth hormone stimulation test in bradykinetic‐rigid parkinsonisms (2008) (9)
Striatal Dopamine Transporter Modulation After Rotigotine: Results From a Pilot Single-Photon Emission Computed Tomography Study in a Group of Early Stage Parkinson Disease Patients (2016) (9)
Occurrence of Takotsubo syndrome in a patient with Parkinson's disease after entacapone add-on. (2014) (9)
Oral thyrotropin-releasing hormone treatment in inherited ataxias. (1988) (9)
Apolipoprotein E Polymorphism and Oxidative Stress in Human Peripheral Blood Cells: Can Physical Activity Reactivate the Proteasome System through Epigenetic Mechanisms? (2020) (9)
From Aberrant Salience to Jumping to Conclusions: Dopaminergic Pathways to Delusions in Parkinson Disease (2013) (9)
Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients (2005) (9)
Iowa gambling task in de novo Parkinson's disease: A comparison between good and poor performers (2012) (8)
Myopathic involvement in two cases of Hallervorden-Spatz disease (1995) (8)
Bilateral thalamic glioma presenting with parkinsonism (2009) (8)
The "closing-in" phenomenon in Parkinson's disease dementia and lewy-body dementia. (2012) (8)
Symptomatic orthostatic tremor associated with Graves’ disease (2014) (8)
Steroid therapy in Huntington's disease. (1992) (8)
[Sleep disturbances in a case of Morvan's chorea (author's transl)]. (1976) (8)
Localized Calcific Hematoma of the Scalp Presenting as a Nummular‐Like Headache. A Case Report (2014) (8)
Non-pharmacological interventions for Parkinson's disease mild cognitive impairment: future directions for research (2020) (7)
Levetiracetam‐responsive myoclonus in spinocerebellar ataxia type 15 (2013) (7)
Mild depressive symptoms are associated with enhanced affective theory of mind in nonclinical adult women. (2014) (7)
Relationship between neuropsychiatric symptoms and cognitive performance in de novo Parkinson's disease. (2012) (7)
A pilot psychometric study of aberrant salience state in patients with Parkinson’s disease and its association with dopamine replacement therapy (2014) (7)
Association Between CSF Beta-Amyloid and Apathy in Early-Stage Alzheimer Disease (2019) (7)
Motor expression of kainic acid seizures is attenuated by dopamine depletion in mice (1994) (7)
Relation between plasmatic and cerebrospinal fluid oxidative stress biomarkers and intrathecal Ig synthesis in Multiple Sclerosis patients (2015) (7)
Effects of Safinamide on Motor Complications and Pain in Advancing Parkinson’s Disease – Post Hoc Analyses of Pivotal Trials (2015) (7)
Detecting cognitive impairment at the early stages: The challenge of first line assessment (2017) (7)
The acute convulsant effect of MPTP is dependent on intracerebral MPP+ (1991) (7)
[Dexamethasone therapy in Huntington chorea: preliminary results]. (1991) (7)
Impairment of affective theory of mind in corticobasal degeneration. (2012) (6)
SUNA Syndrome With Seasonal Pattern (2009) (6)
From Narcissistic Personality Disorder to Frontotemporal Dementia: A Case Report (2011) (6)
Aerobic rehabilitation program for improving muscle function in Parkinson's disease. (2018) (6)
Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson’s Disease (2021) (6)
Epidemiology of progressive supranuclear palsy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. (2001) (6)
Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia (1995) (6)
Oxidative damage and cytogenic analysis in leukocytes of Parkinson's disease patients. Authors' reply (2003) (6)
Familial occurrence of hypothyroidism and cerebellar ataxia. (1991) (6)
Freezing of gait and dementia in parkinsonism: A retrospective case–control study (2019) (6)
Novel MTCYB mutation in a young patient with recurrent stroke‐like episodes and status epilepticus (2014) (6)
The Precuneus – A Witness for Excessive Aβ Gathering in Alzheimer’s Disease Pathology (2019) (6)
Dihydroergocryptine in the treatment of Parkinson's disease. (1995) (6)
Theory of mind in Parkinson’s disease: evidences in drug-naïve patients and longitudinal effects of dopaminergic therapy (2020) (5)
Locus Coeruleus magnetic resonance imaging in cognitively intact elderly subjects (2021) (5)
Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients. (1995) (5)
P2X7 receptor/NLRP3 inflammasome complex and α‐synuclein in peripheral blood mononuclear cells: a prospective study in neo‐diagnosed, treatment‐naïve Parkinson’s disease (2021) (5)
Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease- Cognition (SCOPA-Cog). (2013) (5)
Association study between the DNMT3A -448A>G polymorphism and risk of Alzheimer's disease in Caucasians of Italian origin. (2016) (5)
Valproate‐Withdrawal Induced Migraine (1994) (5)
Evidence for an epileptogenic action of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine. (1989) (5)
NREM sleep transient events in fronto-temporal dementia: beyond sleep stage architecture. (2015) (5)
The safety of dopamine agonists in the treatment of Parkinson's disease (2008) (4)
Risk factors for impulse control disorders and related behaviors in Parkinson’s disease: secondary analyses of the ICARUS study (2019) (4)
Is DAT imaging abnormality in normal pressure hydrocephalus always suggestive of degeneration? (2020) (4)
Apomorphine test in de novo Parkinson's disease. (1992) (4)
Decision-making impairment in a patient with new concomitant diagnoses of Parkinson's disease and HIV. (2009) (4)
Properties of 3H-MPTP binding sites in human blood platelets. (1986) (4)
A case of idiopathic low CSF pressure headache presenting as cough headache (2010) (4)
What Does the Brain Have to Keep Working at Its Best? Resilience Mechanisms Such as Antioxidants and Brain/Cognitive Reserve for Counteracting Alzheimer’s Disease Degeneration (2022) (4)
Bipolar Spectrum disorders in Parkinson’s disease: a systematic evaluation (2020) (4)
Transcranial Direct Current Stimulation (tDCS) as a Useful Rehabilitation Strategy to Improve Cognition in Patients With Alzheimer's Disease and Parkinson's Disease: An Updated Systematic Review of Randomized Controlled Trials (2022) (4)
Pattern of plasma opioids in menstrually-related migraine and epilepsy. (1986) (4)
α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients. (2021) (4)
Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome (2019) (4)
"Cardioembolic profile" in patients with ischemic stroke: data from the analysis of 1037 cases. (2015) (4)
Motor Response to Apomorphine in Patients With Parkinson's Disease With Long-Duration Response to Levodopa (2002) (3)
Contribution of cerebellum and brainstem in the control of eye movement: evidence from a functional study in a clinical model (2002) (3)
Efficacy of a combined therapeutic approach in the management of Pisa Syndrome. (2017) (3)
Impaired attention modulation of the blink reflex R3 component in Parkinson's disease: a non-task warning paradigm study. (2002) (3)
Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: Two case reports (1983) (3)
Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease- Cognition (SCOPA-Cog) (2013) (3)
Clozapine for the treatment of levodopa-induced dyskinesias (2004) (3)
Turning Point towards Blood Biomarker-Guided Targeted Therapy for Precision Medicine in Alzheimer’s Disease (2018) (3)
Erratum: Levodopa in the treatment of Parkinson's disease: Current controversies (Movement Disorders) (2004)) (2005) (3)
Progressive impairment of decision-making in behavioral-variant frontotemporal dementia. (2013) (3)
Intra-arterial tissue plasminogen activator and abciximab in patients with acute basilar artery occlusion (2013) (3)
Association of rs3027178 polymorphism in the circadian clock gene PER1 with susceptibility to Alzheimer’s disease and longevity in an Italian population (2021) (3)
A case of pelvic floor myoclonic jerk syndrome (1996) (3)
Cotard: the man and the syndrome (2010) (3)
Out-of-Control Sexual Behavior in an Orbitofrontal Cortex-Damaged Elderly Patient (2010) (3)
The safety of dopamine agonists in the treatment of Parkinson's disease. (2008) (2)
Ischemic stroke in patients on oral anticoagulant therapy for a cardioembolic risk factor: always due to cardioembolism? (2013) (2)
I.P2 Prevalence of non motor symptoms in Parkinson's Disease: An international survey using NMSQuest in 525 patients (2006) (2)
Imaging in Glucocerebrosidase-Associated Parkinsonism: Current Status and Implications for Pathophysiology (2015) (2)
Functional magnetic resonance imaging with encoding task in patients with mild cognitive impairment and different severity of leukoaraiosis (2018) (2)
Magnetic resonance imaging Locus Coeruleus abnormality in amnestic Mild Cognitive Impairment is associated with future progression to dementia (2022) (2)
Connected speech in progressive supranuclear palsy: a possible role in differential diagnosis (2020) (2)
Platelet monoamine oxidase in dementia of Alzheimer type (1988) (2)
Acute encephalopathy of the temporal lobes leading to m.3243A>G. When MELAS is not always MELAS. (2016) (2)
PLASMA-LEVELS OF CALCIUM, MAGNESIUM, AND PHENOBARBITAL IN EPILEPTIC AND BRAIN TRAUMA PATIENTS ON CHRONIC THERAPY (1982) (2)
P041. Analysis of body mass index, psychiatric comorbidity, sleep-wake pattern and occurrence of fatigue in episodic and chronic migraine patients (2015) (2)
Adrenomyeloneurodystrophy with late cerebral involvement and evidence of a multiple autoimmune disorder (1988) (2)
RE response to: "Entacapone, Parkinson's disease, "functional adrenergic denervation", and Takotsubo syndrome". (2015) (2)
Out-of-control sexual behavior in an orbitofrontal cortex-damaged elderly patient. (2010) (2)
[Amyotrophic lateral sclerosis with multiple myeloma]. (1990) (1)
Epilepsy and Movement Disorders: Seizures and movement disorders precipitated by drugs (2001) (1)
P1.091 Parkinson's disease and pathological gambling: results from a fMRI study investigating cue induced brain activity (2009) (1)
Dopamine Agonist Modifies Cortical Activity in Parkinson Disease: A Functional Neuroimaging Study (2014) (1)
Considerations on hGH and Gonadotropins Incretion in Prepubertal and Pubertal Obese Children (1978) (1)
Peripheral-type benzodiazepine receptors in human blood cells of patients affected by migraine without aura (2000) (1)
Comparison of the effects of barbexaclone and phenobarbital on epileptic patients (1987) (1)
P058. Refractory chronic migraine, fatigue and OnabotulinumtoxinA: a clinic setting experience (2015) (1)
Erratum: Variant of rett syndrome and CDKL5 gene: Clinical and autonomic description of 10 cases (Neuropediatrics (2013) 44 (237-238)) (2013) (1)
Apomorphine-TCD Test: A Clinical Tool to Assess Increased Dopaminergic Sensitivity in Patients with Migraine (1993) (1)
Longitudinal changes in MoCA performances in patients with mild cognitive impairment and small vessel disease. Results from the VMCI-Tuscany Study (2021) (1)
Common Genetic Conditions of Ischemic Stroke to Keep in Mind. (2014) (1)
Effect of lacosamide on sleep-wake cycle of adult patients with drug-resistant partial onset epilepsy (2012) (1)
Corrigendum to “Early detection of wearing off in Parkinson disease: The DEEP study” [Parkinsonism Relat Disorder 20 (2014) 204–211] (2015) (1)
Antagonists of Excitatory Amino Acid Receptors in the Treatment of Parkinson’s Disease (1994) (1)
Alzheimer's disease: Influence of nutritional status on cognitive deficits, behavioral symptoms and caregiver's burden (2010) (1)
Tardive Syndrome Associated With Tetrabenazine in Huntington Disease: A Case Report. (2020) (1)
ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT CHAIN PROTEIN WITH BRAIN AMYLOID STATUS IN A PRECLINICAL COHORT OF SUBJECTIVE MEMORY COMPLAINERS: THE INSIGHT-PREAD STUDY (2017) (1)
Flunarizine increases PRL secretion in normal and in migraineous women (2005) (1)
A Pilot Study Evaluating the Contribution of SLC19A1 (RFC-1) 80G>A Polymorphism to Alzheimer's Disease in Italian Caucasians (2014) (1)
[The apomorphine test for diagnosis of parkinsonian syndrome]. (1990) (1)
Paroxysmal exertion-induced dystonia secondary to Erdheim-Chester disease (2013) (1)
Corticobasal syndrome presenting with partial Gerstmann's syndrome and digit agnosia. (2013) (1)
[OP.1B.02] EFFECT OF A MULTIMODALITY TRAINING ON COGNITIVE AND VASCULAR FUNCTION IN MCI PATIENTS WITH OR WITHOUT HYPERTENSION: THE TRAIN THE BRAIN - MIND THE VESSEL STUDY (2017) (1)
Actigraphic sleep detection: an artificial intelligence approach (2016) (1)
S61. Electroencephalography patterns in patients with thymoma and limbic autoimmune encephalitis: Report of three cases (2018) (1)
[Psychopathological spectrum in behavioral variant frontotemporal dementia]. (2013) (1)
Subject Index Vol. 53, 1991 (1991) (1)
Old and new dopamine agonists in Parkinson's disease: a reappraisal. Introduction. (2009) (1)
Occurrence of seizures and EEG interictal epileptiform discharges in AD patients and their correlation with clinical features: a cross-sectional study (2016) (1)
Mild Cognitive Impairment in de novo Parkinson's Disease: Selective Attention Deficit as Early Sign of Neurocognitive Decay (2021) (1)
Psychopathological disorders in Parkinson’s disease (2011) (1)
International Advanced Training Workshop: Psychosomatic Assessment (2011) (0)
Dissecting the Interplay Between Time of Dementia and Cognitive Profiles in Lewy Body Dementias. (2021) (0)
A case of comorbidity between multiple sclerosis and multiple system atrophy (2011) (0)
perintensities in patients with PD may represent a useful in vivo prognostic marker of rapid disease progression. (2016) (0)
Chronic Migraine With Medication Overuse and OnabotulinumtoxinA: Two Positive Case Reports of a Modified Injection Protocol (2016) (0)
D5 Oxytocin plasma levels as predictor of social cognition in huntington’s disease (2016) (0)
[EEG findings in hemophilia]. (1977) (0)
SPM in the Assessment of the Effect of Dopamine Agonist Drugs on [123I]FP-CIT Imaging: Results in a Group of Patients with Parkinson's Disease (2007) (0)
Anemia and iron overload due to genetic defects of iron recycling, aceruloplasminemia and hemochromatosis type 4 (2002) (0)
P2X7 receptor/NLRP3 inflammasome complex and a-synuclein/parkin balance in neo-diagnosed, treatment-naïve Parkinson disease: a prospective study (2020) (0)
Plasmatic oxidative stress biomarkers in multiple sclerosis patients with different clinical course (2014) (0)
Preservation of the nigro-striatal function in a group of patients with a clinical diagnosis of corticobasal degeneration: evidence from a three-centre FP-CIT SPECT study (2007) (0)
F5 Social cognition in huntington’s disease: evidence from a prospective study (2016) (0)
Domperidoneof its Use in Diabetic Gastropathy (1998) (0)
45. Patient presenting with transient phosphenes and headache: A case of fibromuscular dysplasia (2013) (0)
Impulsivity andcompulsivity in drug-naïve patients with Parkinson's disease (2011) (0)
Apomorphine in the evaluation of dopaminergic sensitivity in migraine (1993) (0)
Thyroid function and oral TRH in amyotrophic lateral sclerosis (1990) (0)
Sleep Disorders in an elderly population and their relationship with cognitive symptoms: an epidemiological survey (2018) (0)
Assessment of the integrity of the noradrenergic nucleus locus coeruleus during normal ageing by neuromelanin‐3T MRI (2020) (0)
Dopaminergic dysfunction and cognitive impairment in Parkinson's disease: Evidence from a SPECT study in a large cohort of de-novo patients (2016) (0)
Serum levels of B subunit creatine kinase isoenzymes measured by a RIA method in patients with brain tumors and stroke. Preliminary results. (1987) (0)
Interference of dopamine agonists on dopamine transporter expression: evidence from an in vivo study (2006) (0)
Assessment of dopaminergic degeneration and rCBF impairment in Alzheimer's Disease and in Lewy body dementia (2002) (0)
Sex differences in red blood cell α ‐synuclein protein and its heteroaggregates with amyloid‐β and tau in early Alzheimer’s disease (2020) (0)
P3443Hippocampal cerebral blood flow depends on systemic endothelial function in individuals with mild cognitive impairment: the Train the Brain-Mind the vessel study (2017) (0)
[The prevalence of active epilepsy in the Commune of Vecchiano, Tuscany]. (1991) (0)
Differential diagnosis of dementia with Lewy Bodies and Alzheimer’s disease by scintigraphic evaluaton of dopaminergic degeneration and selective regional cerebral blood flow impairment (2002) (0)
Sleep inprogressive supranuclear palsy (1982) (0)
Platelet monoamine oxidase Bactivity in Parkinsonian patients (1990) (0)
F43. Electrophysiological tests in patients with anti-MuSK myasthenia gravis: A retrospective study (2018) (0)
Potential Diagnostic Value of Red Blood Cells α-Synuclein Heteroaggregates in Alzheimer’s Disease (2019) (0)
Mild cognitive impairment and cognitivereserve in Parkinson's disease (2011) (0)
Nigrostriatal impairment in Hungtinton's disease: evidences from a [123I]FP-CIT SPECT study (2011) (0)
In vivo assessment of the noradrenergic nucleus locus coeruleus in Alzheimer’s disease and other types of dementia (2020) (0)
FP-CIT SPECT and cognitive performance in de-novo Parkinson's disease patients (2011) (0)
[On the opportunity of treating with hyperbaric oxygenation (hyperbaric oxygen) for the prevention of post-interventional anoxic encephalopathy (delayed neurologic sequelae)]. (1991) (0)
Autonomic function evaluation in De-novo Parkinson's disease (1993) (0)
Chapter 17. Early (Uncomplicated) Parkinson's Disease (2008) (0)
Depressive symptoms inParkinson's disease (2011) (0)
[123I]FP-CIT SPECT in the Evaluation of Parkinson’s Disease: Comparison between Patients with the Tremor and the Rigid-Akynetic Variant (2009) (0)
α-Synuclein heteromers with ß-amyloid and tau decreased in red blood cells of Alzheimer’s disease and Lewy Body dementia patients. (2020) (0)
Reversible MRI abnormalities in mesial temporal lobe epilepsy: a case report (2013) (0)
146 P300 changes in dopaminergic deficiency (1998) (0)
Hippocampal cerebral blood flow depends on systemic endothelial function in individuals with mild cognitive impairment: The Train the Brain-Mind the vessel study (2017) (0)
Cerebral and Extracerebral Abnormalities in Parkinson's Disease-Reply (1996) (0)
Hemodynamic Effects of Apomorphine in Parkinsonian Patients: a TCD Study (1994) (0)
Red blood cell α‐synuclein heteroaggregates can discriminate healthy controls from cognitively impaired subjects of the AD‐LBD spectrum (2020) (0)
[Study of somatotropin incretion during sleep in children with growth retardation]. (1979) (0)
Relationship between isolated mixed tremor and Parkinson’s disease: results from a 123I FP-CIT SPECT and clinical follow-up study (2006) (0)
Cyclic alternating pattern and interictal epileptiform discharges during morning sleep deprived EEG in temporal lobe epilepsy (2017) (0)
Voxel-Based Assessment of Dopaminergic Degeneration and rCBF Changes in Patients with Dementia and Parkinsonism (2007) (0)
Phenobarbitalprophylaxis of post traumatic epilepsy (1980) (0)
I10 In vivo evidence of decreased nigrostriatal terminals in Huntington's disease: a SPECT study (2010) (0)
Preservation of the nigrostriatal function in a group of patients with corticobasal degeneration: evidence from a three-centre FP-CIT SPECT study. (2008) (0)
Relationship between DAT impairment and cognitive performance in drug naive Parkinson's disease (2011) (0)
α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects (2017) (0)
Impulsivity is associated with decision-making deficits in de-novo Parkinson's disease. (2011) (0)
Chapter 18. Late (Complicated) Parkinson's Disease (2008) (0)
Cognitive functions in Parkinson's disease (2010) (0)
Disturbi psicopatologici nella malattia di Parkinson Psychopathological disorders in Parkinson's disease (2011) (0)
PLATELET SEROTONERGIC MARKERS IN MIGRAINE (1992) (0)
β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification (2020) (0)
Clinical Study IGF 1 as a Potential Treatment for Rett Syndrome : Safety Assessment in Six Rett Patients (2012) (0)
A molecular signature in blood identifies early Parkinson’s disease (2012) (0)
Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study (2019) (0)
Poster Presentations (2023) (0)
Acetylcholinesterase inhibitors in Parkinson’s disease with dementia: a clinical and brain perfusional study (2004) (0)
PINK1 mutations cause typical late-onset Parkinson's disease as well as early-onset Parkinsonism. (2006) (0)
Clinical usefulness of creatine kinase BB determination by a RIA method in serum of patients with cerebrovascular accidents. (1988) (0)
Hippocampal morphometry in MCI patients at 7T and correlations with clinical assessment (2016) (0)
Subacute Alzheimer’s disease with prominent white matter involvement. Report of a pathologically-confirmed case (2013) (0)
Reply: Dopamine agonists and delusional jealousy in Parkinson's disease: A cross‐sectional prevalence study (2013) (0)
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (0)
Circadian rhythm in gonadotropin secretion in children with constitutional stature delay. (1979) (0)
Predictive value of [123I]FP-CIT-SPECT on surgical outcome in idiopathic adult chronic hydrocephalus: A pilot study (2016) (0)
[The intensity-of-care model at the Versilia Hospital]. (2012) (0)
P.2.c.008 Assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease (2010) (0)
PREDICTION PERFORMANCE OF ALPHA-SYNUCLEIN PROTEIN IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY AD BIOMARKERS: THE INSIGHT-PRE AD STUDY (2017) (0)
25 Three years follow-up outcome of deferiprone for pantothenate kinase-associated neurodegeneration (PKAN) (2012) (0)
Dopamine transporter imaging does not discriminate between Multiple System Atrophy and Parkinson’s Disease: evidence on patient populations with clinical diagnosis confirmed by specific MRI criteria (2006) (0)
Clinical and Neuroendocrinological Effects of Estrogens in Postmenopausal Women with Parkinson’s Disease (1991) (0)
Profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis: a clinical and laboratory study. (2014) (0)
Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study (2022) (0)
INFLUENCES OF DOPAMINERGIC TREATMENT OF MOTOR CORTEX IN PD: A MRI/MRS STUDY (2007) (0)
The role of sleep microstructure in the diagnostic yield ofEEG after sleep deprivation in temporal lobe epilepsy (2016) (0)
Preserved presynaptic nigrostriatal function in parkinsonism occurring in Alzheimer’s disease:evidente from a dopamine transporter imaging study (2003) (0)
Parkinson’s disease and pathological gambling: preliminary results from an fMRI study investigating cue induced brain activity (2009) (0)
Parkinsonism and dementia: in vivo differentiation between Alzheimer’s disease, Lewy Body dementia, and Parkinson’s disease with dementia by a double-tracer SPECT study (2003) (0)
Decision-making impairment may precede limb apraxia in corticobasal degeneration. (2011) (0)
Reply from the Authors (1995) (0)
Negative DAT‐SPECT in Old Onset Parkinson's Disease: An Additional Pitfall? (2022) (0)
Predictive Value of [123I]FP-CIT SPECT in the Assessment of Patients with Isolated Mixed Tremor (2005) (0)
Acetylcholinesterase inhibitors in Parkinson’s disease (PD) with dementia: a clinical and rCBF SPET study (2004) (0)
Reduced glutathione s-transferase activity in plasma from parkinson's disease but not Alzheimer's disease patients☆ (2000) (0)
Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study (2020) (0)
Asymptomatic cardiac arrhythmias in periodic paralysis. (1988) (0)
Variant of Rett Syndrome and CDKL5 Gene: Clinical and Autonomic Description of 10 Cases (2013) (0)
PROCEEDINGS of the XVI CONGRESS OF THE ITALIAN SOCIETY OF MYOLOGY Lecce, Italy June 8-11, 2016 (2016) (0)
Comparison between Parkinson’s disease dementia and Lewy body disease: A double tracer SPECT approach by using SPM (2010) (0)
The relationship between clinical measurements and gait analysis data in patients with Parkinson's disease and postural deformities (2016) (0)
Abstracts Third congress of the european society for clinical neuropharmacology (1996) (0)
Involvement of retinal subsystems in "de novo" Parkinson's disease (2000) (0)
Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study (2022) (0)
Evaluation of a new radioimmunological assay for the determination of the B subunit of creatine kinase enzyme. (1984) (0)
Parkinsonism and dementia: in vivo differentiation between Alzheimer’s disease and Lewy Body dementia by a double-tracer SPECT study. (2003) (0)
Lack of interference of dopamine agonists on Dopamine Transporter expression: evidence from a [123I]FP-CIT SPECT in patients with Parkinson’s Disease (2006) (0)
Abstracts Second Congress of the European Society for Clinical Neuropharmacology (1995) (0)
DIAGNOSTIC PERFORMANCE USING CSF YKL-40 IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA (2017) (0)
Molecular defects in two genetic disorders of iron recycling: aceruloplasminemia and hemochromatosis type 4 (2002) (0)
The effect of dopamine agonist drugs on [123I]FP-CIT imaging in patients with Parkinson¹s Disease (2006) (0)
Multiple Sclerosis and Neurofibromatosis type1: case report (2015) (0)
Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease (2018) (0)
Decision-Making Impairment May Precede Limb Apraxia in Corticobasal Degeneration (2011) (0)
Obstructive sleep apnea, hypothyroidism and cognition (2014) (0)
DISRUPTION OF SLEEP-WAKE CONTINUUM IN MYOTONIC DYSTROPHY TYPE I: SLEEP MACROSTRUCTURAL AND MICROSTRUCTURAL FINDINGS (2017) (0)
HIPPOCAMPAL CEREBRAL BLOOD FLOW DEPENDS ON SYSTEMIC ENDOTHELIAL FUNCTION IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT: THE TRAIN, THE BRAIN-MIND, THE VESSEL STUDY (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ubaldo Bonuccelli?

Ubaldo Bonuccelli is affiliated with the following schools: